Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioScrip names new COO
Mr Smith will report to Richard Friedman, BioScrip’s chairman and CEO, and will begin work on or before January 2, 2009, after a short transition period with his
Mr Smith will report to Richard Friedman, BioScrip’s chairman and CEO, and will begin work on or before January 2, 2009, after a short transition period with his
Tapentadol tablets have been approved in 50mg, 75mg and 100mg doses. The approval was based on data from clinical studies involving more than 2,100 patients. The studies showed
The agreement adds to the existing pharmaceutical agents focused on targets in oncology and inflammation being developed by the Hutchison MediPharma group for Lilly. Under the agreement, Hutchison
The company, which has bases in the UK, the US and Romania, said that it will use the new funds from Scottish Equity Partners (SEP) to expand its
The study encompasses both patients with very high triglycerides and mixed dyslipidemia and includes normal weight, overweight and obese patients presenting with or without hypertension. The randomized, double-blind
The agreement outlines the proposed terms for establishing a joint venture (JV) company, which will seek to co-develop seasonal influenza vaccines and pre-pandemic or pandemic influenza vaccines, firstly
In these patients, RoActemra can be given as monotherapy in cases of intolerance to methotrexate (MTX) or where continued treatment with MTX is inappropriate. RoActemra is said to
Filgrastim is indicated for use in treating neutropenia, a condition characterized by lack of neutrophils – one of the most common types of white blood cells – that
The submission was through the centralized procedure and this new formulation allows once-daily dosing: Competact (pioglitazone HCl and metfomin HCl) is currently available in some European countries as
Naproxcinod 750mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo. Following the positive results from the 301 and 302